RG

Repligen CorpDUS Repligen Stock Report

Last reporting period 30 Sep, 2024

Updated 02 Dec, 2024

Last price

Market cap $B

8.001

Middle

Exchange

XDUS - Boerse Duesseldorf

RGN.DU Stock Analysis

RG

Uncovered

Repligen Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

24/100

Low score

Market cap $B

8.001

Dividend yield

Shares outstanding

55.563 B

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,025 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.

View Section: Eyestock Rating